Need access to NeoLink? Contact your Sales rep or our Client Services team at 866.776.5907, Option 3

April 16, 2025

Your acute myeloid leukemia (AML) patients may be eligible for the IDHNow for AML Sponsored Testing Program.

This exclusive program provides the IDH1/IDH2 Mutation Analysis by PCR test at no additional cost to patients for those who meet the eligibility criteria:

• Patient is newly diagnosed AML, and not previously treated
• Patient lives and receives treatment in the U.S. or a U.S. territory
• The patient does not have a known IDH1 mutation from a previous test
• The patient has not previously been tested under this program

To learn more and order today, visit: please visit our website.

To serve our customers and their patients, we evaluate our test menu regularly to align with clinical guidelines. Effective May 12th, we will improve our test offerings to serve your diagnostic needs. While specific tests will be discontinued, we have thoroughly evaluated and identified more appropriate tests from our menu that align with recommended guidelines. Below is a comprehensive list of affected tests and their recommended replacements.

Orders for the NeoTYPE^® Discovery Profile and replaced tests will not be automatically converted. Please order the new test using the appropriate requisition form or the online ordering portal to avoid testing delays.

For a complete list of test updates, click here.